GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Other Liabilities for Insurance Companies

Larimar Therapeutics (STU:ZA71) Other Liabilities for Insurance Companies


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Other Liabilities for Insurance Companies?

Other Liabilities for Insurance Companies only applies to insurance companies.


Larimar Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.